Labeling cyclic glycoprotein IIb/IIIa receptor antagonists with Tc-99m by the preformed chelate approach: Effects of chelators on properties of [Tc-99m]chelator-peptide conjugates

被引:85
作者
Liu, S
Edwards, DS
Looby, RJ
Poirier, MJ
Rajopadhye, M
Bourque, JP
Carroll, TR
机构
[1] Radiopharmaceuticals Division, DuPont Merck Pharmaceutical Company, North Billerica, MA 01862
关键词
D O I
10.1021/bc9500958
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Several cyclic GPIIb/IIIa receptor antagonists were labeled with Tc-99m by the preformed chelate approach using chelators such as H(4)L1 [4,5-bis(mercaptoacetamido)pentanoic acid], H(4)L2 [3,4-bis-(mercaptoacetamido)benzoic acid], H(3)L3 [2-(mercapto)ethylaminoacetyl-L-cysteine], H(4)L4 [N-(mercaptoacetyl)glycylglycylglycine], H(4)L5 [N-[2-(mercapto)propionyl]glycylglycylglycine], and H(4)L6 [N-[2-(mercapto)propionyl]glycylglycyl-gamma-aminobutyric acid]. In this approach, the [Tc-99m]chelator complexes are formed first, followed by the activation of the carboxylic group on the complex by formation of its tetrafluorophenol (TFP) ester and the conjugation of the TFP ester with an amino group of a cyclic GPIIb/IIIa receptor antagonist. The Tc-99m-labeled cyclic GPIIb/IIIa receptor antagonists were characterized by radio-HPLC (high-performance liquid chromatography); differences in lipophilicity of the [Tc-99m]chelator-peptide conjugate are attributable to the effects of both the cyclic peptide and the chelator.
引用
收藏
页码:196 / 202
页数:7
相关论文
共 36 条
[1]  
ABRAMS MJ, 1990, J NUCL MED, V31, P2022
[2]   CONFORMATIONALLY CONSTRAINED PEPTIDES AND SEMIPEPTIDES DERIVED FROM RGD AS POTENT INHIBITORS OF THE PLATELET FIBRINOGEN RECEPTOR AND PLATELET-AGGREGATION [J].
ALI, FE ;
BENNETT, DB ;
CALVO, RR ;
ELLIOTT, JD ;
HWANG, SM ;
KU, TW ;
LAGO, MA ;
NICHOLS, AJ ;
ROMOFF, TT ;
SHAH, DH ;
VASKO, JA ;
WONG, AS ;
YELLIN, TO ;
YUAN, CK ;
SAMANEN, JM .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (06) :769-780
[3]  
BABICH JW, 1993, J NUCL MED, V34, P1967
[4]  
BAIDOO KE, 1994, J NUCL MED, V35, pP19
[5]  
BARRETT JA, 1994, J NUCL MED, V35, pP52
[6]   Biological evaluation of Tc-99m-labeled cyclic glycoprotein IIb/IIIa receptor antagonists in the canine arteriovenous shunt and deep vein thrombosis models: Effects of chelators on biological properties of [Tc-99m]chelator-peptide conjugates [J].
Barrett, JA ;
Damphousse, DJ ;
Heminway, SJ ;
Liu, S ;
Edwards, DS ;
Looby, RJ ;
Carroll, TR .
BIOCONJUGATE CHEMISTRY, 1996, 7 (02) :203-208
[7]   SYNTHESIS AND LABELING CHARACTERISTICS OF TC-99M-MERCAPTOACETYLTRIPEPTIDES [J].
BORMANS, G ;
CLEYNHENS, B ;
ADRIAENS, P ;
DEROO, M ;
VERBRUGGEN, A .
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 1993, 33 (11) :1065-1078
[8]  
BREITZ HB, 1992, J NUCL MED, V33, P1099
[9]   DESIGN AND SYNTHESIS OF NOVEL CYCLIC RGD-CONTAINING PEPTIDES AS HIGHLY POTENT AND SELECTIVE INTEGRIN ALPHA(IIB)BETA(3) ANTAGONISTS [J].
CHENG, S ;
CRAIG, WS ;
MULLEN, D ;
TSCHOPP, JF ;
DIXON, D ;
PIERSCHBACHER, MD .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (01) :1-8
[10]   A NEW CLASS OF OXOTECHNETIUM(5+) CHELATE COMPLEXES CONTAINING A TCON2S2 CORE [J].
DAVISON, A ;
JONES, AG ;
ORVIG, C ;
SOHN, M .
INORGANIC CHEMISTRY, 1981, 20 (06) :1629-1632